Sapient Fact Sheet

At Sapient, we believe that drugs can be developed much faster, cheaper, and more effectively through biomarker-driven drug discovery. Biomarkers allow us to better align the right patient with the right disease biology and ultimately the right therapy – and this alignment is what allows for more efficient and successful development.

That is why we have developed a transformative, three-pronged platform to enable biomarker identification with unprecedented speed and at population scale – and then make them actionable to optimize drug pipelines and advance clinical development.

Using our transformative, three-pronged platform – starting with untargeted mass spectrometry discovery screenings – we identify small molecule biomarkers with unprecedented speed and at an entirely new scale.

Download the fact sheet to learn everything that comprises the platform’s integrated pillars, including our longitudinal Human Biology Database of data from >100,000 human biosamples, rLC-MS systems for nontargeted mass spectrometry profiling of small molecule biomarkers, and expert bioinformatics team that provides the insights to rapidly discover and validate biomarkers to answer key drug development questions.